Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Results | NCT00368875 | the primary trial results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00368875', 'Intervention': ['INTERVENTION 1: ', ' Phase I', ' Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration. Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.', ' All patients also received paclitaxel at 90 mg/m2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 92680a4c-a1e0-47d2-9b7f-cacb20cd1fde | |
Single | Eligibility | NCT02550210 | Patients must have cancer that can be felt by touch to be eligible for the primary trial. | Entailment | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT02550210', 'Intervention': ['INTERVENTION 1: ', ' Breast Cancer Locator (BCL)', ' The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b3dd4e23-f78c-4bf9-9268-d1018c966980 | |
Single | Results | NCT01997333 | The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01997333', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine', ' Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study.', 'INTERVENTION 2: ', ' CDX-011', ' CDX-011 administere... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 553d7721-289e-4ab1-a9b9-7b2c939f47c1 | |
Single | Adverse Events | NCT00894504 | There were no adverse event in the primary trial which occurred more than 71 times. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00894504', 'Intervention': ['INTERVENTION 1: ', ' Panitumumab/Gemcitabine/Carboplatin', ' Panitumumab - 6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks) Carboplatin - AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks) Gemcitabine - 1500 mg/m2 IV,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 01c6f82e-710d-4fa4-aa62-2d26e72f4533 | |
Comparison | Eligibility | NCT02018458 | NCT00895414 | Patients with unexplained fever exceeding 39°C are excluded from the primary trial but may be included in the secondary trial. | Entailment | [
25,
28
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT02018458', 'Intervention': ['INTERVENTION 1: ', ' LA TNBC: DC Vaccine+Preop Chemo', ' LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemothera... | {'Clinical Trial ID': 'NCT00895414', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin Hydrochloride Alone', ' Participants who received doxorubicin hydrochloride alone in either Cycle 1 or Cycle 2.', 'INTERVENTION 2: ', ' Doxorubicin Hydrochloride With Enalapril', ' Participants who received doxorubicin hydrochlo... | 2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc |
Comparison | Results | NCT00295620 | NCT03366428 | the secondary trial and the primary trial employ non comparable outcome measures. | Entailment | [
0,
1,
2
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00295620', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Anastrozol', ' 1 mg per day for 2 years', 'INTERVENTION 2: ', ' Arm B: Anastrozol', ' 1 mg per day for 5 years'], 'Eligibility': ['Inclusion criteria:', ' Postmenopausal patients with histologically confirmed, local radically treate... | {'Clinical Trial ID': 'NCT03366428', 'Intervention': ['INTERVENTION 1: ', ' DS-8201a', ' Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Has a pathologically documented unresectable or metast... | 862c0bfe-10a6-453c-9ada-929dd00141a0 |
Single | Eligibility | NCT01094184 | A patient who had an oophorectomy in the last month would not be eligible for the primary trial. | Entailment | [
4,
7
] | [] | {'Clinical Trial ID': 'NCT01094184', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab 10 mg/kg Q2W', ' Participants received bevacizumab at a dose of 10 mg/kg Q2W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f | |
Single | Intervention | NCT00343863 | On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00343863', 'Intervention': ['INTERVENTION 1: ', ' Dexamethasone + Ondansetron IV', ' All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.', ' Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubic... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5501dae3-0d3c-4812-96c2-35ca863e24a5 | |
Comparison | Intervention | NCT02005887 | NCT00050011 | All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle, for the same duration of time. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4
] | {'Clinical Trial ID': 'NCT02005887', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Triptorelin + Letrozol', ' Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles', ' Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycle... | {'Clinical Trial ID': 'NCT00050011', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Upfront', ' Participants in the upfront arm received Zoledronic Acid 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence)or the end of study. Participants also received Letrozole 2.5 daily plus calcium ... | ece8e7df-790d-4e26-9c34-40cf66d2abf5 |
Comparison | Intervention | NCT00077376 | NCT01256008 | the primary trial investigates a novel radiotherapy treatment, whereas the secondary trial is testing a type of psychological therapy. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00077376', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab/Ixabepilone/Carboplatin', ' During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cyc... | {'Clinical Trial ID': 'NCT01256008', 'Intervention': ['INTERVENTION 1: ', ' Stage 1 Clinical Management', ' The group will receive clinical management treatment only each session.', ' Clinical Management: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview an... | 550a36e2-43bb-40af-b0c8-49498fbe2c8c |
Comparison | Adverse Events | NCT02102490 | NCT00768222 | In contrast to the secondary trial, the primary trial did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation . | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT02102490', 'Intervention': ['INTERVENTION 1: ', ' Abemaciclib', ' 200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.'], 'Eligibility': ['Inclusion Criteria.', ' Have a diagnosis of... | {'Clinical Trial ID': 'NCT00768222', 'Intervention': ['INTERVENTION 1: ', ' Chinese Silk Suture', ' Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern', 'INTERVENTION 2: ', ' VICRYL* Plus Suture',... | 95869347-6c3d-4de8-a325-a9a652f11edf |
Single | Adverse Events | NCT00509769 | 3/112 patients (2.68%) in the primary trial had Diabetes insipidus | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00509769', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine 3.6 mg/kg', " Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle."], 'Eligib... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8df8e2c0-a0ca-4ea2-ba83-494f250c4bef | |
Single | Intervention | NCT02556632 | Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT02556632', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Curcumin-based Gel)', ' Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', 'Curcumin-based ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1d4a385f-1c72-4c61-8d49-9ada0e3b716a | |
Single | Results | NCT01091428 | The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by results from cohort 2 of the primary trial, is 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17 | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01091428', 'Intervention': ['INTERVENTION 1: ', ' Alisertib + Paclitaxel (Phase 1)', ' Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b15aa13a-fbd9-4b2e-9dd2-b16628084d07 | |
Single | Results | NCT00246571 | Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00246571', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib', ' SU011248 (Sutent [sunitinib malate, hereafter referred to as sunitinib]) oral capsules, 37.5 milligrams (mg) once daily (QD) in a continuous regimen, expressed in 3-week cycles. 1-week treatment rests and dose reductions allowed... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c9214d06-2733-4c78-99e5-a42015908eae | |
Comparison | Intervention | NCT02660788 | NCT01490892 | the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is not. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02660788', 'Intervention': ['INTERVENTION 1: ', ' Control Arm', ' Mail', ' Standard Reminder Postcard', 'INTERVENTION 2: ', ' Family Physician Reminder Letter Arm', ' Mail', ' Standard Reminder Postcard', ' Family Physician Reminder Letter'], 'Eligibility': ['Inclusion Criteria:', ' Ac... | {'Clinical Trial ID': 'NCT01490892', 'Intervention': ['INTERVENTION 1: ', ' 3D HI and SHI of UCA', ' Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)', ' 3D HI and SHI of UCA: Perflutren injection, suspension (IV)0.25 m... | a318fc31-4f28-4356-b09a-59741bb7c97a |
Single | Results | NCT00206518 | The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22
] | [] | {'Clinical Trial ID': 'NCT00206518', 'Intervention': ['INTERVENTION 1: ', ' A: Taxotere/Docetaxel', ' Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 70ec4bc8-f8fa-4901-aa7a-2388b53960c6 | |
Comparison | Eligibility | NCT00570323 | NCT00193180 | Female patients with a womb cannot take part in either the secondary trial or the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | {'Clinical Trial ID': 'NCT00570323', 'Intervention': ['INTERVENTION 1: ', ' ARM A / Arimidex With Faslodex', ' Arimidex with Faslodex in postmenopausal women', ' Arimidex: Aromatase inhibitors', ' Faslodex: Hormone Receptor', 'INTERVENTION 2: ', ' ARM B Arimidex Without Faslodex', ' Arimidex without Faslodex in p... | {'Clinical Trial ID': 'NCT00193180', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beg... | 00dc0e37-1d0b-4f53-a037-86bf9799dae6 |
Comparison | Eligibility | NCT01663727 | NCT00072293 | Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | [
16,
17,
18
] | {'Clinical Trial ID': 'NCT01663727', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel+Placebo', ' Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.', 'INT... | {'Clinical Trial ID': 'NCT00072293', 'Intervention': ['INTERVENTION 1: ', ' Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', 'INTERVENTION... | a1a421cc-01c9-4afb-8f09-6b10b0ff5094 |
Single | Results | NCT00246571 | Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00246571', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib', ' SU011248 (Sutent [sunitinib malate, hereafter referred to as sunitinib]) oral capsules, 37.5 milligrams (mg) once daily (QD) in a continuous regimen, expressed in 3-week cycles. 1-week treatment rests and dose reductions allowed... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9316ef0d-55b0-4547-88ae-887e0132a263 | |
Comparison | Intervention | NCT01929395 | NCT01857882 | the primary trial and the secondary trial are both utilising test and control groups in their interventions. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT01929395', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Addition of Supine MRI to Conventional Imaging', ' Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)'], 'Eligibility': ['Inclusion Criteria Phase 1', ' Age greater than/equal to 18 years', ' His... | {'Clinical Trial ID': 'NCT01857882', 'Intervention': ['INTERVENTION 1: ', ' Decision Support Workshop', ' The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.', ' Decision Support Workshop: Incorporates... | 5d815fac-c66c-43fe-9ac8-a352b6e47a5b |
Single | Adverse Events | NCT00127205 | More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations. | Entailment | [
10,
17,
18
] | [] | {'Clinical Trial ID': 'NCT00127205', 'Intervention': ['INTERVENTION 1: ', ' Arm I Zoledronate', ' Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.', ' zoledronic acid: Given IV', 'INTERVENTION 2: ', ' Arm II Clodronate', ' Patients receive oral c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7b9fdeaa-5cb7-4453-b174-07b44bb58234 | |
Single | Adverse Events | NCT00875979 | None of the 60+ patients in cohort 2 the primary trial experienced any adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31
] | [] | {'Clinical Trial ID': 'NCT00875979', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg', ' Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer the... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c330f152-c64e-47ab-8568-5129a1a2099e | |
Single | Adverse Events | NCT00811135 | The majority of patients in the primary trial did not experience Left ventricular dysfunction. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00811135', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Bevacizumab + Capecitabine', ' Participants received IV trastuzumab (8 mg/kg) for first cycle and then 6 mg/kg for subsequent cycles followed by bevacizumab (15 mg/kg) on Day 1 of each treatment cycles along with capecitabine ad... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e3b88c8c-241d-4ead-8573-534a46210707 | |
Single | Adverse Events | NCT00022516 | At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00022516', 'Intervention': ['INTERVENTION 1: ', ' No-CM', ' No further chemotherapy following standard adjuvant chemotherapy.', 'INTERVENTION 2: ', ' CM-Maintenance', ' 12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e621f354-dea0-4d0f-a252-5480028c1712 | |
Single | Results | NCT00244881 | 30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00244881', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cediranib Maleate)', ' Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must ha... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ee209156-74dc-475e-87af-ae51160982ef | |
Single | Results | NCT01519700 | There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01519700', 'Intervention': ['INTERVENTION 1: ', ' EP2006 + EP2006 & Neupogen', ' All subjects randomized to receive either EP2006 in Cycle 1', 'INTERVENTION 2: ', ' Neupogen + Neupogen & EP2006', ' All subjects randomized to receive Neupogen in Cycle 1'], 'Eligibility': ['Inclusion Criteri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | edf813c0-2271-49ca-a040-a355bf71d8b4 | |
Single | Eligibility | NCT01827163 | Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for the primary trial. | Contradiction | [
13,
14
] | [] | {'Clinical Trial ID': 'NCT01827163', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel With Trastuzumab and Lapatinib', " Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegf... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 352475ea-1b17-4d1a-a5e3-71f1b87cffd8 | |
Single | Adverse Events | NCT00544167 | Every adverse event in the primary trial occurred more than 8 times. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00544167', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin/Cyclophosphamide Then Paclitaxel/Sorafenib', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically-confirmed breast cancer with an interval between definitive surgery that includes axillary... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c7c745d6-03ee-4740-9ef4-641fb6546e46 | |
Comparison | Adverse Events | NCT00617942 | NCT00388726 | the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00617942', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1', '[Not Specified]', 'INTERVENTION 2: ', ' Cohort 2', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented adenocarcinoma of the breast', ' ANC > 1000 cells', ' Female; age > 18; Zubrod PS 0-1', '... | {'Clinical Trial ID': 'NCT00388726', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/kg^2', ' Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatment of Physician's Choice"], 'Eligibility': ['Inclusion Criteria:', ' Female patients with hi... | c5c8ab0b-8062-4467-8ecd-bb15f35f54c0 |
Single | Results | NCT01827787 | The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01827787', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: HR+/HER2-', ' Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle', ' Participants remained on single agent eribulin until disease progression or withdrawal for other reasons.', 'INT... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 601e9c47-ed82-4fa6-8a28-b3c71cc7c71b | |
Single | Eligibility | NCT00191854 | Patients must have a one bi-dimensional, measurable indicator lesion to be included in the primary trial | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00191854', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Paclitaxel', ' Gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.', ' Paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles', 'INTERVENTION 2: ', ' Gemcitabine + Carboplatin', ' G... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8f1959e4-b93a-4112-9726-27a4034f0e07 | |
Single | Eligibility | NCT00254592 | Patients must have an ECOG score below 3 to participate in the primary trial. | Entailment | [
0,
9
] | [] | {'Clinical Trial ID': 'NCT00254592', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy With GM-CSF', ' Doxorubicin and Cyclophosphamide (AC) with Granulocyte-macrophage colony-stimulating factor (GM-CSF) (days 4-13) Followed by Weekly Carboplatin/Nab- Paclitaxel'], 'Eligibility': ['Inclusion Criteria:', ' Patients... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e1782960-8d44-4acc-aaae-bfa4f8e38de0 | |
Comparison | Eligibility | NCT00365599 | NCT01771666 | Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial | Contradiction | [
0,
10,
12,
15,
25
] | [
0,
6
] | {'Clinical Trial ID': 'NCT00365599', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat and Tamoxifen', ' Vorinostat and Tamoxifen as outlined in Intervention Descriptions'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have cytologically/histologically documented locally advanced or metastatic breast cance... | {'Clinical Trial ID': 'NCT01771666', 'Intervention': ['INTERVENTION 1: ', ' ISB and IC-Green Dye', ' The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 20... | 61bd93b2-b38f-496d-acd9-f8b188d28a39 |
Single | Intervention | NCT02667626 | the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT02667626', 'Intervention': ['INTERVENTION 1: ', ' SCPR Intervention', ' Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive heal... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 741c95c7-825c-4321-8d12-9037bb701ab8 | |
Single | Results | NCT00305448 | At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT00305448', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg', 'Fulvestrant 250 mg', 'INTERVENTION 2: ', ' Fulvestrant 250 mg + Loading Dose', ' Fulvestrant 250 mg + Loading Dose'], 'Eligibility': ['Inclusion Criteria:', ' Breast Cancer has continued to grow after having received t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6ce047b6-c18f-4f63-90ec-8643f5145efe | |
Comparison | Intervention | NCT02781051 | NCT01067976 | The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, in contrast a full year of daily physical exercise is explicitly required for the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02781051', 'Intervention': ['INTERVENTION 1: ', ' Physical Activity Intervention', ' Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.', ' Print-based education: Subjects were given a copy of Exercise for Health: An Exer... | {'Clinical Trial ID': 'NCT01067976', 'Intervention': ['INTERVENTION 1: ', ' CMRM vs UMRM', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology [ACR... | d647aad0-47f7-4b77-a265-e77dcf5e0983 |
Comparison | Results | NCT00841828 | NCT01959490 | All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00841828', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: EC -> D + Lapatinib', ' EC -> D + Lapatinib', ' Drugs plus Biological', ' Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -> Docetaxel (D) + lapatinib each 21 days for 4 cycles)', 'INTERVENTION 2: ', ' Arm 2: EC -> D + ... | {'Clinical Trial ID': 'NCT01959490', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1P (HER2 Positive)', ' Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1... | 74fed085-3389-49c6-bdd2-a95c97071f2d |
Single | Eligibility | NCT00450723 | There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24
] | [] | {'Clinical Trial ID': 'NCT00450723', 'Intervention': ['INTERVENTION 1: ', ' Sentinel Lymph Node Biopsy', '[Not Specified]'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer', ' Stage I or II disease (T1-T2, N0, M0/MX disease)', ' No chest wall invasion by tumor (T3 disease)', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 986ffe33-8e8b-4cbf-8408-eb9489fb2314 | |
Comparison | Adverse Events | NCT00483223 | NCT00811135 | There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in the secondary trial than in the primary trial | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00483223', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin or Carboplatin', ' Cisplatin or carboplatin (1 arm, 2 cohorts)', ' Cisplatin: Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their dis... | {'Clinical Trial ID': 'NCT00811135', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Bevacizumab + Capecitabine', ' Participants received IV trastuzumab (8 mg/kg) for first cycle and then 6 mg/kg for subsequent cycles followed by bevacizumab (15 mg/kg) on Day 1 of each treatment cycles along with capecitabine ad... | aeac5b1c-26f9-44bc-b1c4-3bd0d498914e |
Single | Eligibility | NCT02455453 | Patients with tumors that are HER2 +, PR and ER -, are eligible for the primary trial. | Contradiction | [
0,
10
] | [] | {'Clinical Trial ID': 'NCT02455453', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic FFNP-PET/CT Scan', ' (2) 18F-FFNP-PET/CT scans', ' First one prior to estradiol challenge test', ' Second one immediately following one day of estradiol challenge test', ' (1) FDG-PET/CT scan at screening', ' The estradiol chal... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3f98cd71-ec28-4fd1-9ca0-2184eef3390a | |
Comparison | Intervention | NCT01912612 | NCT02392611 | In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the same intervention. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01912612', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Patients With Pain)', ' Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.', ' Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then ... | {'Clinical Trial ID': 'NCT02392611', 'Intervention': ['INTERVENTION 1: ', ' Monotherapy: Alobresib 0.6 mg', ' Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once ... | 11138479-1666-4973-84c2-c6779b5444f5 |
Comparison | Adverse Events | NCT02402764 | NCT00490646 | There were no cases of Pneumopathy in either the primary trial or the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT02402764', 'Intervention': ['INTERVENTION 1: ', ' Selinexor Treatment', ' Ten patients were treated with oral selinexor 60 mg twice per week (on days 1 and 3) on a schedule of 3 weeks on and 1 week off, each four-week cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirm... | {'Clinical Trial ID': 'NCT00490646', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV', ' trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptabl... | 35c62055-2832-4119-9080-5603beea1934 |
Comparison | Eligibility | NCT02244580 | NCT01901146 | Patients with undetermined human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial. | Entailment | [
0,
3
] | [
0,
5
] | {'Clinical Trial ID': 'NCT02244580', 'Intervention': ['INTERVENTION 1: ', ' Luminal A', ' Patients subtyped as Luminal A with DDFS determined 5 years after randomisation', 'INTERVENTION 2: ', ' Combined Subtype', ' Patients subtyped as Luminal B, HER2 positive, triple negative with DDFS determined 5 years after ran... | {'Clinical Trial ID': 'NCT01901146', 'Intervention': ['INTERVENTION 1: ', ' ABP 980', ' Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.', 'INTERVENTI... | 59ff0501-f6af-4739-bd07-71e12e8cd8a7 |
Single | Eligibility | NCT00605267 | Men are not eligible for the primary trial. | Entailment | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00605267', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole 1 mg', ' Anastrozole (investigational product) 1mg tablet given once a day orally and goserelin acetate 3.6 mg/ month depot injection', 'INTERVENTION 2: ', ' Tamoxifen 20 mg', ' Tamoxifen (comparator) 20mg tablet given once a da... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ab52c559-5712-44ff-becd-1c491e107472 | |
Comparison | Adverse Events | NCT01629615 | NCT00320541 | the secondary trial recorded more cardiac related adverse events than the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01629615', 'Intervention': ['INTERVENTION 1: ', ' BKM120', ' BKM120: BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression'], 'Eligibility': ['Inclusion Criteria:', ' Pathologically and radiologically confirmed metastatic TNBC (Stage IV disease), previously docu... | {'Clinical Trial ID': 'NCT00320541', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel Plus Bevacizumab (PB)', ' paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15... | 4619b957-3368-47b9-b949-01ec91208f96 |
Comparison | Adverse Events | NCT00559754 | NCT02924883 | A higher percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial. | Entailment | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00559754', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel', ' Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevaci... | {'Clinical Trial ID': 'NCT02924883', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine + Placebo', ' Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or stu... | 5bb09d7b-622f-4bdd-8dfd-809ea014a278 |
Comparison | Results | NCT00435409 | NCT00319254 | The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00435409', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib + Capecitabine', ' Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen. Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day (1000 mg/m^2 BID) from Days 1-14 every 3 w... | {'Clinical Trial ID': 'NCT00319254', 'Intervention': ['INTERVENTION 1: ', ' Bosutinib', ' Four bosutinib 100 milligram (mg) capsules, equivalent to 400 mg bosutinib orally once daily for 48 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent occurred.'], 'Eligibility': ['Inclusion Crit... | 07327b61-973b-48bb-b42b-dfde1efcfb7d |
Single | Eligibility | NCT00633750 | Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial. | Entailment | [
0,
1,
4,
10
] | [] | {'Clinical Trial ID': 'NCT00633750', 'Intervention': ['INTERVENTION 1: ', ' Tarceva', ' Following a pre-treatment core breast biopsy, participants are given Tarceva at a dose of 150 mg/day by mouth for 5-14 days. Within 24 hours of their last dose of Tarceva, participants undergo a post-treatment resection of their t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3307a083-0c8a-47b8-94cb-0bf4095b9c3b | |
Comparison | Adverse Events | NCT03165955 | NCT00912340 | 11 patients in the primary trial suffer from a liver disease, 0 in the secondary trial. | Entailment | [
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT03165955', 'Intervention': ['INTERVENTION 1: ', ' Oraxol (Oral Paclitaxel Plus HM30181)', ' Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Signed written informed consent', ' Women 18 years of age on day of consent', ' Breast cancer ... | {'Clinical Trial ID': 'NCT00912340', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab a... | bda2752e-082e-4d06-926a-04ade3f61c26 |
Single | Results | NCT00118157 | Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00118157', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Patients receive oral lapatinib and oral tamoxifen once daily on days 1-28.', ' lapatinib ditosylate: Given orally', ' tamoxifen citrate: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' Primary adenocarcinoma of the brea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d4d73d33-4f71-46b2-b0c1-eac6741fd8f3 | |
Single | Adverse Events | NCT01127763 | There were 4 more cases of Dyspnea than Dehydration in the primary trial. | Contradiction | [
3,
6
] | [] | {'Clinical Trial ID': 'NCT01127763', 'Intervention': ['INTERVENTION 1: ', ' RAD001+Carboplatin', ' Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.', 'RAD001', 'Carbop... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f418c027-439a-4b19-bfb0-e1c1241886d8 | |
Single | Eligibility | NCT00009945 | Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00009945', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Clodronate', ' Patient receives 2 tablets once daily for 3 years.', ' clodronate: 1600 mg PO daily', 'INTERVENTION 2: ', ' Arm 2: Placebo', ' Patient receives 2 tablets once daily for 3 years.', ' placebo: 2 pills PO daily'], 'Elig... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4805e49a-b99e-46d8-b937-13ac2501c4a4 | |
Single | Results | NCT01091428 | The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17 | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01091428', 'Intervention': ['INTERVENTION 1: ', ' Alisertib + Paclitaxel (Phase 1)', ' Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9a3cb836-66a8-4c68-980c-97e5841f331f | |
Single | Eligibility | NCT00553410 | A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33
] | [] | {'Clinical Trial ID': 'NCT00553410', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Continuous Letrozole', ' Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)', ' Letrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously', 'INTERVENTION 2: ', ' Arm B: Intermittent Let... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45d4f78f-04d4-434c-9679-fd92291e97b6 | |
Single | Adverse Events | NCT01365845 | Less than a quarter of participants in the primary trial had radiation dermatitis. | Entailment | [
3
] | [] | {'Clinical Trial ID': 'NCT01365845', 'Intervention': ['INTERVENTION 1: ', ' Conventional Photon Plan', ' Photon: 50.4 Gray (Gy) to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction', 'INTERVENTION 2: ', ' 3D-Proton/Conventional Plan or 3D-proton Only', ' 3D-Proton/Conventional plan or 3D-proto... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5338f894-aecb-4678-bb67-fe058653e12b | |
Single | Intervention | NCT01953003 | Patients receiving intervention 1 of the primary trial, will be administered medication topically and intraveinously. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT01953003', 'Intervention': ['INTERVENTION 1: ', ' Arm A : iv Vinflunine Plus Capecitabine', ' Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.', ' vi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2cebae78-f4a3-4e09-ac54-cd2388670274 | |
Comparison | Results | NCT01516736 | NCT00733408 | the primary trial and the secondary trial have non comparable results as the metrics they records are completely different. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01516736', 'Intervention': ['INTERVENTION 1: ', ' LA-EP2006', ' During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.', ' LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemothe... | {'Clinical Trial ID': 'NCT00733408', 'Intervention': ['INTERVENTION 1: ', ' Tx (Chemo, MoAb, and Enzyme Inhibitor)', ' INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 d... | d8a98ace-009c-47e4-a812-3bc0df91ed2b |
Single | Intervention | NCT00300781 | Participants of the primary trial are assigned an intervention depending on their hormone recpetor status. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00300781', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 240, Prior Trastuzumab', ' Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment.', 'INTERV... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c8cfd67e-5fac-4bff-9296-6e42dcb09f80 | |
Comparison | Intervention | NCT01376349 | NCT01912612 | Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT01376349', 'Intervention': ['INTERVENTION 1: ', ' Arm I Low Dose DHEA', ' Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to ... | {'Clinical Trial ID': 'NCT01912612', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Patients With Pain)', ' Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.', ' Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then ... | 57cf3760-1692-439f-bbe2-82a6bc8862ce |
Single | Eligibility | NCT00364611 | Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial. | Entailment | [
18
] | [] | {'Clinical Trial ID': 'NCT00364611', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and Bevacizumab', ' Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxici... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7db1447c-b4e8-49c6-a125-8161bcd98560 | |
Comparison | Results | NCT00550771 | NCT00143390 | over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia, with the majority of those coming from the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00550771', 'Intervention': ['INTERVENTION 1: ', ' Pegylated Liposomal Doxorubicin (PLD) Based Regimen', ' PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) ... | {'Clinical Trial ID': 'NCT00143390', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.', 'INTERV... | 626a05e9-2caf-4e73-a132-5432a5b2c7d9 |
Comparison | Adverse Events | NCT00066573 | NCT01091454 | There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00066573', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Patients receive oral exemestane (25 mg) once daily for 5 years.', ' exemestane: Given orally', 'INTERVENTION 2: ', ' Anastrozole', ' Patients receive oral anastrozole (1 mg) once daily for 5 years.', ' anastrozole: Given o... | {'Clinical Trial ID': 'NCT01091454', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cisplatin and Brostallicin)', ' Patients receive 50 mg/m^2 cisplatin IV over 2 hours on day 1 and 10 mg/m^2 brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptabl... | fe6f3faf-8be6-4ec6-8622-b4d36e8c2876 |
Single | Eligibility | NCT00186121 | Patients with E2 outside the premenopausal range are ineligible for the primary trial. | Contradiction | [
5
] | [] | {'Clinical Trial ID': 'NCT00186121', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole + Goserelin', ' Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily.'], 'Eligibility': ['INCLUSION CRITERIA'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b1cd4818-9623-45e5-a2b3-4c80016e3c82 | |
Comparison | Intervention | NCT03061175 | NCT03098550 | Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03061175', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Web-Based CPM-DA)', ' Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.', ' Internet-Based Intervention: Receive web-based CPM-DA', ' Survey Administration: Ancillary... | {'Clinical Trial ID': 'NCT03098550', 'Intervention': ['INTERVENTION 1: ', ' Nivolumab + Daratumumab (TNBC)', ' Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/... | 3050bca2-a8bc-412e-b679-5be1055e3749 |
Single | Adverse Events | NCT02001974 | No cases of Metastasis to the CNS were recorded in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02001974', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)', 'INTERVENTION 2: ', ' Group 2', ' Paclitaxel 80 mg/m2 i.v. (Da... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a49666fd-f278-4dcf-b6bf-287ace3969aa | |
Comparison | Results | NCT00445458 | NCT00950742 | the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame and the same unit of measure. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00445458', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 160 mg + Paclitaxel 80 mg/m²', ' Neratinib 160 mg qd + Paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle.', 'INTERVENTION 2: ', ' Neratinib 240 mg + Paclitaxel 80 mg/m²', ' Neratinib 240 mg qd + Paclitaxel 80 mg/m² IV ... | {'Clinical Trial ID': 'NCT00950742', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 20mg + Herceptin', ' Patients received continuous daily dosing with Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or lack of clinical benefit. This group includes pat... | f6c014af-63db-4578-9b2d-74ea95901842 |
Comparison | Intervention | NCT02660788 | NCT01490892 | the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is evaluating the impact of regular exercise and dieting. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02660788', 'Intervention': ['INTERVENTION 1: ', ' Control Arm', ' Mail', ' Standard Reminder Postcard', 'INTERVENTION 2: ', ' Family Physician Reminder Letter Arm', ' Mail', ' Standard Reminder Postcard', ' Family Physician Reminder Letter'], 'Eligibility': ['Inclusion Criteria:', ' Ac... | {'Clinical Trial ID': 'NCT01490892', 'Intervention': ['INTERVENTION 1: ', ' 3D HI and SHI of UCA', ' Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)', ' 3D HI and SHI of UCA: Perflutren injection, suspension (IV)0.25 m... | c8ef1457-63a9-4eac-a98b-edb805afd35b |
Comparison | Eligibility | NCT03097653 | NCT00662129 | Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial. | Entailment | [
0,
1,
2,
3,
4
] | [
4,
5,
6
] | {'Clinical Trial ID': 'NCT03097653', 'Intervention': ['INTERVENTION 1: ', ' Decision-aid', " Decision-aid: Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screen... | {'Clinical Trial ID': 'NCT00662129', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel + Gemcitabine + Bevacizumab', ' Patients receive 125 mg/m^2 paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and 1000 mg/m^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and 15 mg/kg bevaci... | 515d0710-429b-4c28-b881-8a6531ee973e |
Single | Intervention | NCT02104895 | Neither cohorts of the primary trial receive any medication orally or by IV. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT02104895', 'Intervention': ['INTERVENTION 1: ', ' Whole Breast Irradiation (WBI)', ' Conventional whole breast irradiation (WBI)', ' Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)', 'INTERVENTION 2: ', ' Partial Breast Irradiation (APBI)', ' Accelerated partia... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b4d261a4-9b42-4158-9b21-159859b59e2a | |
Single | Eligibility | NCT00293540 | Males are not eligible for the primary trial, because they do not produce oestrogen. | Contradiction | [
0,
1,
2,
3,
4
] | [] | {'Clinical Trial ID': 'NCT00293540', 'Intervention': ['INTERVENTION 1: ', ' A Mid-luteal Surgery', '[Not Specified]', 'INTERVENTION 2: ', ' B Mid-follicular Surgery', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Estrogen receptor or progesterone receptor positive breast cancer', ' Premenopausal with... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1c043d17-15a9-496c-a69b-9ec95a7ab8df | |
Single | Eligibility | NCT00328783 | Patients with a COPD diagnosis through spirometry are ineligible for the primary trial. | Entailment | [
0,
2
] | [] | {'Clinical Trial ID': 'NCT00328783', 'Intervention': ['INTERVENTION 1: ', ' Active Breathing Coordinator', ' Patients breathe through the ABC device', ' Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 79c69498-7dd5-41fa-8946-36d452a5b9ec | |
Single | Results | NCT00633464 | Cohort 2 of the primary trial reported worse results than cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00633464', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks', 'INTERVENTION 2: ', ' Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2', ' cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligib... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 93fc76a9-5f3d-490b-8802-21d0fa806728 | |
Single | Intervention | NCT02104895 | Neither cohorts of the primary trial receive any medication orally, by IV or by radiation. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT02104895', 'Intervention': ['INTERVENTION 1: ', ' Whole Breast Irradiation (WBI)', ' Conventional whole breast irradiation (WBI)', ' Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)', 'INTERVENTION 2: ', ' Partial Breast Irradiation (APBI)', ' Accelerated partia... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9f5e55af-8a94-4531-ab00-f16199795b64 | |
Single | Eligibility | NCT00945061 | patients with Multicentric breast cancer can be accepted for the primary trial. | Contradiction | [
0,
3
] | [] | {'Clinical Trial ID': 'NCT00945061', 'Intervention': ['INTERVENTION 1: ', ' Intraoperative Radiation Therapy', ' Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.', 'INTERVENTION 2: ', ' Intracavitary Balloon Brachytherapy', ' Patients undergo partial... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ee85e355-3d0a-4e40-8a8d-6a0b71c77148 | |
Single | Eligibility | NCT00629499 | Patients with peripheral neuropathy resulting in intolerable paresthesias, are excluded from the primary trial. | Entailment | [
0,
13
] | [] | {'Clinical Trial ID': 'NCT00629499', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' 100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment per... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c4a2ca0b-c4a7-4366-92c7-145dadd38af3 | |
Single | Eligibility | NCT00399529 | Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement, are eligible for the primary trial. | Contradiction | [
8
] | [] | {'Clinical Trial ID': 'NCT00399529', 'Intervention': ['INTERVENTION 1: ', ' Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide', ' Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c6ca8c6a-7eae-4671-9eff-c44a1222fadb | |
Single | Adverse Events | NCT01674062 | One patient in the primary trial was observed vomiting blood. | Entailment | [
3
] | [] | {'Clinical Trial ID': 'NCT01674062', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab (Cohorts 1 and 2)', ' Females with HER2-positive metastatic breast cancer received dual-agent treatment with pertuzumab and trastuzumab. Recruitment for Cohorts 1 and 2 was conducted separately; however, the same regi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e591b3bb-0628-46e7-9d60-28989fd6a3d0 | |
Single | Results | NCT00463788 | Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00463788', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin and Cetuximab', ' Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 75da6329-e8a1-4808-bb0f-78fd3a2dde9c | |
Comparison | Adverse Events | NCT01629615 | NCT00320541 | the secondary trial recorded more cardiac related adverse events than the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01629615', 'Intervention': ['INTERVENTION 1: ', ' BKM120', ' BKM120: BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression'], 'Eligibility': ['Inclusion Criteria:', ' Pathologically and radiologically confirmed metastatic TNBC (Stage IV disease), previously docu... | {'Clinical Trial ID': 'NCT00320541', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel Plus Bevacizumab (PB)', ' paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15... | dab9d582-eaf3-443f-bdb9-073aec304ee6 |
Comparison | Adverse Events | NCT00265759 | NCT00866905 | One case of hematolysis was recorded in the primary trial, none in the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00265759', 'Intervention': ['INTERVENTION 1: ', ' Cohort A Arm I: Exemestane', ' Patients receive oral exemestane 25 mg once daily for up to 16-18 weeks prior to partial or radical mastectomy or lumpectomy with or without lymph node dissection', 'INTERVENTION 2: ', ' Cohort A Arm II: Letroz... | {'Clinical Trial ID': 'NCT00866905', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone/Cyclophosphamide', ' Systemic Therapy followed by surgery and possible radiation therapy'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, age 18 years.', ' Histologically confirmed invasive adenocarcinoma of the brea... | 8b9bb672-1de3-4220-956c-9e86ed78063d |
Comparison | Intervention | NCT00712985 | NCT02038010 | Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00712985', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid 5 mg IV', ' Zometa (Zoledronic Acid) 5 mg IV given over 15 minutes as a one time dose. Follow-up at month 1 & every 2 months to month 12 for serum & urine markers of bone destruction (NTx & CTx).'], 'Eligibility': ['Inclusion ... | {'Clinical Trial ID': 'NCT02038010', 'Intervention': ['INTERVENTION 1: ', ' Cohort -1 (250mg BYL719, 3.6mg/kg T-DM1)', ' Patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). Courses repeat every 21 days in the absence of dis... | 3194a043-d156-49d6-97bb-81867ed188f0 |
Single | Eligibility | NCT01027416 | To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test. | Entailment | [
0,
3,
8
] | [] | {'Clinical Trial ID': 'NCT01027416', 'Intervention': ['INTERVENTION 1: ', ' No Intervention', ' No Intervention: Standard of care', 'INTERVENTION 2: ', ' Tamoxifen', ' Tamoxifen 20 mg orally 1x/day for 4 weeks', ' Tamoxifen: Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks'], 'Eligibility': ['Inclusion Criteria:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8c3ab1eb-c473-4399-b18c-512ef16e4a47 | |
Comparison | Intervention | NCT00902330 | NCT00952731 | the primary trial and the secondary trial only have test cohorts in their studies. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00902330', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Cranial Microcurrent Electrical Stimulation [CES])', ' Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is pr... | {'Clinical Trial ID': 'NCT00952731', 'Intervention': ['INTERVENTION 1: ', ' Treatment Gel + Oral Placebo', ' 4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.', ' oral placebo: Oral placebo taken daily for 4-10 weeks.', ' afimoxifene: 2mg/breast applied daily in the form of a gel for 4-10 w... | aeac1009-91c3-40ad-8583-5b548e1f4b3b |
Single | Results | NCT00240071 | At least one participant of the primary trial survived over 200 days without documented disease progression. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00240071', 'Intervention': ['INTERVENTION 1: ', ' Avastin (Bevacizumab) Plus Hormone', ' All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.'], 'Eligibility': ['Inclusion Criteria:', ' Patients mu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3058d104-172e-41be-b641-9f0f9cb172be | |
Single | Adverse Events | NCT01439282 | In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2. | Entailment | [
0,
1,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01439282', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Eribulin Mesylate Plus 900 mg/m^2 Capecitabine', ' Eribulin mesylate (1.4 mg/m^2) was injected directly as an IV infusion over 2 to 5 minutes on Day 1 and Day 8 of the 21-day cycle for a total of 4 cycles. Alternatively, eribulin me... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bc845a3d-1f69-41a3-bf84-36a62e8127a4 | |
Comparison | Eligibility | NCT00570323 | NCT00193180 | Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
8,
18
] | {'Clinical Trial ID': 'NCT00570323', 'Intervention': ['INTERVENTION 1: ', ' ARM A / Arimidex With Faslodex', ' Arimidex with Faslodex in postmenopausal women', ' Arimidex: Aromatase inhibitors', ' Faslodex: Hormone Receptor', 'INTERVENTION 2: ', ' ARM B Arimidex Without Faslodex', ' Arimidex without Faslodex in p... | {'Clinical Trial ID': 'NCT00193180', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beg... | 69ced998-f3c9-460a-a272-b2c95421b89d |
Single | Intervention | NCT00354640 | Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00354640', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole and Simvastatin', ' adjuvant therapy : laboratory analysis', ' pharmacological study : laboratory analysis', ' simvastatin : 40 milligram tablet PO QD for 14 days', ' anastrozole : 1 milligram tablet PO QD for 14 days'], 'Eligi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45fb84a3-674c-40f5-ac8c-26a3c7844e7b | |
Single | Intervention | NCT00146172 | Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00146172', 'Intervention': ['INTERVENTION 1: ', ' Neratinib 40 mg', 'Neratinb 40 mg qd', 'INTERVENTION 2: ', ' Neratinib 80 mg', 'Neratinib 80 mg qd'], 'Eligibility': ['Inclusion Criteria:', ' Her2/neu or Her1/EGFR positive cancer', ' Eastern Cooperative Oncology Group (ECOG) performance s... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c349cad6-8b63-4e5e-9b87-4fc08bb6fc30 | |
Single | Adverse Events | NCT00912340 | More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1. | Entailment | [
0,
7,
8,
15
] | [] | {'Clinical Trial ID': 'NCT00912340', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9 | |
Comparison | Intervention | NCT01448447 | NCT03252145 | the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device, which patients must use themselves to drain their lymph vessels. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT01448447', 'Intervention': ['INTERVENTION 1: ', ' Sole Method', ' patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS', ' Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions ... | {'Clinical Trial ID': 'NCT03252145', 'Intervention': ['INTERVENTION 1: ', ' Manual Lymph Drainage', ' Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb vol... | b3effb24-6ec0-4fa3-9c91-74a45bcc4602 |
Single | Intervention | NCT03106077 | Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT03106077', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Advanced Triple-Negative Breast Cancer (TNBC)', ' 6 mg/kg IMGN853 IV Q3W'], 'Eligibility': ['Inclusion Criteria:', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Confirmed invasive triple-negative bre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9026c2ff-2dd8-4aa9-b2fb-f6bef856189d | |
Comparison | Adverse Events | NCT00083174 | NCT00190671 | The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT00083174', 'Intervention': ['INTERVENTION 1: ', ' Open-label Extension: Exemestane', ' one 25 mg tablet daily in am', ' exemestane: one 25 mg tablet daily in am'], 'Eligibility': ['At increased risk of developing breast cancer, due to at least one of the following risk factors:', ' Gail sc... | {'Clinical Trial ID': 'NCT00190671', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed 600mg/m2', ' Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles', 'INTERVENTION 2: ', ' Pemetrexed 1800mg/m2', ' Pemetrexed: 1800 mg/m2, intravenous, ev... | 341c0861-b9a3-491d-8d49-aa61a8501a4f |
Single | Adverse Events | NCT00915018 | The only cases of Leukopenia in the primary trial occurred in cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00915018', 'Intervention': ['INTERVENTION 1: ', ' Neratinib + Paclitaxel', ' Neratinib + Paclitaxel', ' Neratinib: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 16d6e554-a1df-42f9-b051-947d70595cbb | |
Single | Eligibility | NCT00316199 | Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00316199', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine + Paclitaxel', ' Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression.', ' Paclitaxel: 175 mg/m2, intravenous (IV), every 21 days until disease progression'], 'Eligibility': ['Inclusi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8f0159ce-1044-4f31-94b7-e394cf91d4e1 | |
Comparison | Adverse Events | NCT00688909 | NCT00129376 | Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00688909', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with HR+ early stage breast cancer at the time of i... | {'Clinical Trial ID': 'NCT00129376', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed Docetaxel', ' Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles (days 1, 22, 43 and 64). Three weeks late... | ccc5e420-dda4-4fb9-8d68-82551d69017f |
Single | Eligibility | NCT00429104 | Patients with end-stage liver disease are excluded from the primary trial. | Entailment | [
7,
12
] | [] | {'Clinical Trial ID': 'NCT00429104', 'Intervention': ['INTERVENTION 1: ', ' HER2+ Metastatic Breast Cancer', ' Herceptin 4 mg/kg intravenous (IV) Over 90 Minutes + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 250 mcg/m^2 subcutaneously'], 'Eligibility': ['Inclusion Criteria:', ' Histological confirmatio... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 89f8ba8c-e626-4bd4-9994-3d0264018932 | |
Single | Results | NCT00375505 | In the primary trial patients in the test group had better health outcomes than the control group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00375505', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).', 'INTERVENTION 2: ', ' Zometa', ' Zoledronic Acid 4mg as a 15-minute infusion every 3 months for a treatment period of 2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d | |
Comparison | Results | NCT01129336 | NCT01945775 | More than half the participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT01129336', 'Intervention': ['INTERVENTION 1: ', ' Patients Without Bone Metastases', ' Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.', 'INTERVENTION 2: ', ' Patient... | {'Clinical Trial ID': 'NCT01945775', 'Intervention': ['INTERVENTION 1: ', ' Talazoparib', " Participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or spo... | 57e6f0e1-6157-43bc-8bdf-c3649ed49133 |
Comparison | Intervention | NCT02725801 | NCT04030104 | Neither the primary trial or the secondary trial have control groups. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT02725801', 'Intervention': ['INTERVENTION 1: ', ' One-port', ' intervention is placement of one-port tissue expander at time of reconstruction', ' Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruc... | {'Clinical Trial ID': 'NCT04030104', 'Intervention': ['INTERVENTION 1: ', ' IUS Alone', 'IUS alone imaging', 'INTERVENTION 2: ', ' Imagio (IUS+OA)', 'IUS+OA imaging'], 'Eligibility': ['Inclusion Criteria:', ' One analyzable mass per patient: BI-RADS 3 and 4a, 4b, 4c and 5 masses as declared by clinical site investig... | 300dbe96-0be8-4ca0-aa3b-41bc059bac7f |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.